Targeting cancer with antibody-drug conjugates: Promises and challenges

Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the U.S. Food and Drug Administration (FDA) has approved ten ADCs, namely Adcetris®, Kadcyla®, Besponsa®, Mylotarg®, Poli...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:MAbs
Prif Awduron: Dean, Alexis Q., Luo, Shen, Twomey, Julianne D., Zhang, Baolin
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Taylor & Francis 2021
Pynciau:
Review
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8300931/
https://ncbi.nlm.nih.gov/pubmed/34291723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2021.1951427
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg